Ionis Pharmaceuticals Reports Q4 Loss, Exceeding Expectations

CARLSBAD, Calif., March 8, 2023 – Ionis Pharmaceuticals Inc. (IONS) reported a quarterly loss of $104 million, translating to a loss of 66 cents per share. Analysts' consensus estimate was a loss of $1.12 per share.

Revenue for the quarter reached $227 million, outperforming the $137.4 million consensus forecast.

For the full year, Ionis recorded a loss of $454 million ($3.04 per share) on revenue of $705 million.